Intrinsic Value of S&P & Nasdaq Contact Us

CSL Limited CSLLY OTC

Other OTC • Healthcare • Biotechnology • AU • USD

SharesGrow Score
77/100
6/7 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
Analyst Price Target
$307.00
+1139.4%

CSL Limited (CSLLY) generated $3.56B in operating cash flow for fiscal year 2025. After capital expenditures of $1.02B, free cash flow was $2.54B.

Free cash flow margin was 16.5% of revenue.

The company returned $1.43B in dividends to shareholders during the period.

Criteria supported by this page:

  • HEALTH (67/100, Partial) — cash generation is adequate but may not fully cover debt in stressed conditions
  • MOAT (75/100, Pass) — $2.54B (16.5% FCF margin) supports a durable competitive advantage

Overall SharesGrow Score: 77/100 with 6/7 criteria passed.

SharesGrow 7-Criteria Score
77/100
SG Score
View full scorecard →
VALUE
62/100
Price-to-Earnings & upside
→ Valuation
FUTURE
100/100
Analyst consensus
→ Forecast
PAST
100/100
→ Income
~
HEALTH
67/100
Debt-to-Equity & liquidity
Proven by this page
MOAT
75/100
Proven by this page
GROWTH
63/100
→ Income
INCOME
70/100
→ Income
CSL Limited Cash Flow History
Metric TTM FY2025 FY2024 FY2023 FY2022
Operating Cash Flow $6.71B$3.56B$2.76B$3.87B$3.62B
Capital Expenditure $-1.67B$-1.02B$-1.26B$-2.52B$-1.72B
Free Cash Flow $5.04B$2.54B$1.51B$1.35B$1.9B
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
Send us a message